Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Active, not recruiting · NCT05696717 · Registry updated 2025-09-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, primary dysautonomia, vascular disorder | Active, not recruiting | Phase 3 | 2025-09-05 | NCT05696717 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Theravance Biopharma | 3 |
76 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.